Literature DB >> 18031201

Apoptosis in pulmonary fibrosis: too much or not enough?

Cheryl L Fattman.   

Abstract

Apoptosis plays an important role in both normal lung homeostasis and lung remodeling associated with fibrotic lung disease. Whether apoptosis promotes or inhibits the pathogenesis of pulmonary fibrosis depends upon the cell type involved and the microenvironment of the affected lung. Undue cell loss in the alveolar epithelium may be important early in idiopathic pulmonary fibrosis (IPF) progression, while reduced fibroblast and myofibroblast apoptosis has been associated with the formation of fibrotic lesions. As such, novel therapies based on the stimulation or inhibition of apoptosis may prove beneficial to the treatment of patients with IPF.

Entities:  

Mesh:

Year:  2008        PMID: 18031201     DOI: 10.1089/ars.2007.1907

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  28 in total

1.  Role of vasoactive intestinal peptide in hyperoxia-induced injury of primary type II alveolar epithelial cells.

Authors:  Xiaoxiao Ao; Fang Fang; Feng Xu
Journal:  Indian J Pediatr       Date:  2010-10-07       Impact factor: 1.967

Review 2.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

3.  Gender influences the response to experimental silica-induced lung fibrosis in mice.

Authors:  David M Brass; Sean P McGee; Mary K Dunkel; Sarah M Reilly; Jacob M Tobolewski; Tara Sabo-Attwood; Cheryl L Fattman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-08-20       Impact factor: 5.464

4.  miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2.

Authors:  Marta Fierro-Fernández; Óscar Busnadiego; Pilar Sandoval; Cristina Espinosa-Díez; Eva Blanco-Ruiz; Macarena Rodríguez; Héctor Pian; Ricardo Ramos; Manuel López-Cabrera; Maria Laura García-Bermejo; Santiago Lamas
Journal:  EMBO Rep       Date:  2015-08-27       Impact factor: 8.807

Review 5.  Epigenetics in lung fibrosis: from pathobiology to treatment perspective.

Authors:  Britney A Helling; Ivana V Yang
Journal:  Curr Opin Pulm Med       Date:  2015-09       Impact factor: 3.155

Review 6.  Epigenomics of idiopathic pulmonary fibrosis.

Authors:  Ivana V Yang
Journal:  Epigenomics       Date:  2012-04       Impact factor: 4.778

Review 7.  Myofibroblast differentiation and survival in fibrotic disease.

Authors:  Kornelia Kis; Xiaoqiu Liu; James S Hagood
Journal:  Expert Rev Mol Med       Date:  2011-08-23       Impact factor: 5.600

Review 8.  Interstitial lung diseases in children.

Authors:  Annick Clement; Nadia Nathan; Ralph Epaud; Brigitte Fauroux; Harriet Corvol
Journal:  Orphanet J Rare Dis       Date:  2010-08-20       Impact factor: 4.123

9.  MUC5B and Idiopathic Pulmonary Fibrosis.

Authors:  Ivana V Yang; Tasha E Fingerlin; Christopher M Evans; Marvin I Schwarz; David A Schwartz
Journal:  Ann Am Thorac Soc       Date:  2015-11

10.  Neuropeptide substance P attenuates hyperoxia-induced oxidative stress injury in type II alveolar epithelial cells via suppressing the activation of JNK pathway.

Authors:  Bo Huang; Hongmin Fu; Ming Yang; Fang Fang; Fengwu Kuang; Feng Xu
Journal:  Lung       Date:  2009-09-30       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.